Healing Hearts - Saving Lives

The first transcatheter solution that combines repair and replacement for Mitral or Tricuspid valve in one procedure

The Team

Founders

The Opportunity

Globally there are more than 15 million Mitral Regurgitation (MR) patients, 4.5 million are suffering from severe MR

Only 2% of the 4.5 million severe MR  patients undergo open heart surgery.

The remaining 98% are sent home with drug therapy alone, resulting in nearly 50% of them dying within two years

The treatments available for MR patients with heart failure are limited. Surgical repair and replacement are controversial,  and new treatments are insufficient

VALFIX is developing the first complete trans-catheter solution that combines repair and replacement treatments, offering a viable alternative to open heart surgery

Based on its multi-wire technology, VALFIX technology is designed to eliminate Mitral Regurgitation in over 90% of severe MR patients

VALFIX is creating a solution that is the closest to the surgical standard in trans-catheter mitral valve repair and replacement

Get in touch with us! We would love to hear from you